Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions

被引:32
作者
Martens, Pieter [1 ,2 ]
Verbrugge, Frederik H. [1 ]
Nijst, Petra [1 ,2 ]
Dupont, Matthias [1 ]
Mullens, Wilfried [1 ,3 ]
机构
[1] Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium
[2] Hasselt Univ, Fac Med & Life Sci, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium
[3] Hasselt Univ, Biomed Res Inst, Fac Med & Life Sci, Diepenbeek, Belgium
关键词
EUROPEAN-SOCIETY; ASSOCIATION HFA; RENAL-FUNCTION; TASK-FORCE; IMPLANTATION; GUIDELINES; FUROSEMIDE; DIAGNOSIS; SODIUM; ESC;
D O I
10.1016/j.amjcard.2017.04.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac resynchronization therapy (CRT) improves cardiac hemodynamics. Therefore, the maintenance dose of loop diuretic therapy might be reduced. Consecutive patients who underwent CRT (n = 648) were retrospectively evaluated. Loop diuretic dose was recorded at baseline before implantation and 6 months later with patients classified into 4 groups: (1) no loop diuretic, (2) down-titration, (3) unchanged dose, and (4) up-titration. Afterward total loop diuretic exposure was calculated. Renal function trajectories were evaluated as the difference between implantation and censoring serum creatinine (Cr) value. Clinical outcome was evaluated as the combined end point of heart failure readmissions and all cause mortality. Independent predictors of successful loop diuretic down-titration were identified. Two hundred ninety-six patients (46%) received no loop diuretic at follow-up, 126 (19%) underwent down-titration, 137 (21%) remained on a stable dose, and 89 (14%) underwent up-titration. In comparison with the group that was free from loop diuretics (Cr = +0.06 mg/dl), renal function deteriorated faster during follow-up in patients on stable doses (Cr = +0.29 mg/dl; p = 0.045) and those underwent up-titration (Cr = +0.44 mg/dl; p = 0.009) but not in patients who were down-titrated (Cr = +0.13 mg/dl; p = 1.00). Patients receiving down-titration had a lower risk for the combined clinical end point (adjusted hazards ratio 0.43; confidence interval 0.22 to 0.83; p = 0.012). Factors associated with successful down-titration after 6 months of CRT included nonischemic cardiomyopathy, higher baseline dose of diuretics, higher ejection fraction at 6 weeks, and lower right ventricular systolic pressure at 6 weeks. In conclusion, after CRT, down titration of loop diuretics is often feasible and associated with improved outcome and a slower rate of kidney function decline. Patients with nonischemic cardiomyopathy, treated with high doses of loop diuretics before implantation and beneficial left ventricular remodeling with CRT, are most likely to tolerate loop diuretic down-titration. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:267 / 273
页数:7
相关论文
共 25 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]   Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure [J].
Bonfils, Peter K. ;
Damgaard, Morten ;
Taskiran, Mustafa ;
Goetze, Jens Peter ;
Norsk, Peter ;
Gadsboll, Niels .
EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (09) :995-1001
[3]  
Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004
[4]   Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction [J].
Cooper, HA ;
Dries, DL ;
Davis, CE ;
Shen, YL ;
Domanski, MJ .
CIRCULATION, 1999, 100 (12) :1311-1315
[5]   Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction [J].
Damman, Kevin ;
Kjekshus, John ;
Wikstrand, John ;
Cleland, John G. F. ;
Komajda, Michel ;
Wedel, Hans ;
Waagstein, Finn ;
McMurray, John J. V. .
EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (03) :328-336
[6]   The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction [J].
Dries, DL ;
Exner, DV ;
Domanski, MJ ;
Greenberg, B ;
Stevenson, LW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (03) :681-689
[7]   Relation of loop diuretic dose to mortality in advanced heart failure [J].
Eshaghian, Shervin ;
Horwich, Tamara B. ;
Fonarow, Gregg C. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12) :1759-1764
[8]   BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy [J].
Gottlieb, SS ;
Brater, DC ;
Thomas, I ;
Havranek, E ;
Bourge, R ;
Goldman, S ;
Dyer, F ;
Gomez, M ;
Bennett, D ;
Ticho, B ;
Beckman, E ;
Abraham, WT .
CIRCULATION, 2002, 105 (11) :1348-1353
[9]  
Kapelios CJ, 2015, HELL J CARDIOL, V56, P154
[10]   Pathobiology of cardiac dyssynchrony and resynchronization [J].
Kass, David A. .
HEART RHYTHM, 2009, 6 (11) :1660-1665